-
Product Insights
Eosinophilic Esophagitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis – Drugs In Development, 2022, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape. Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and...
-
Product Insights
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important...
-
Product Insights
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2022, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape. Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome...
-
Product Insights
Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy – Drugs In Development, 2022, provides an overview of the Peanut Allergy (Immunology) pipeline landscape. Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such...
-
Product Insights
Haemophilus Influenzae Type B Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections – Drugs In Development, 2022, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape. Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include...
-
Product Insights
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa – Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape. Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the...
-
Product Insights
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections – Drugs In Development, 2022, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in...
-
Product Insights
Chronic Urticaria or Hives Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives – Drugs In Development, 2022, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape. Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 33 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor – Drugs In Development, 2022, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and...